A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS3110-TPS3110
◽